Literature DB >> 26175298

Insensitivity of Human iPS Cells-Derived Mesenchymal Stem Cells to Interferon-γ-induced HLA Expression Potentiates Repair Efficiency of Hind Limb Ischemia in Immune Humanized NOD Scid Gamma Mice.

Yue-Qi Sun1,2, Yuelin Zhang3,4, Xin Li5, Meng-Xia Deng1,2, Wen-Xiang Gao1,2, Yin Yao1,2, Sin-Ming Chiu3, Xiaoting Liang3, Fei Gao4, Camie W Chan6, Hung-Fat Tse3, Jianbo Shi1,2, Qing-Ling Fu1,2, Qizhou Lian3,4,7.   

Abstract

Adult mesenchymal stem cells (MSCs) are immunoprivileged cells due to the low expression of major histocompatibility complex (MHC) II molecules. However, the expression of MHC molecules in human-induced pluripotent stem cells (iPSCs)-derived MSCs has not been investigated. Here, we examined the expression of human leukocyte antigen (HLA) in human MSCs derived from iPSCs, fetuses, and adult bone marrow (BM) after stimulation with interferon-γ (IFN-γ), compared their repair efficacy, cell retention, inflammation, and HLA II expression in immune humanized NOD Scid gamma (NSG) mice of hind limb ischemia. In the absence of IFN-γ stimulation, HLA-II was expressed only in BM-MSCs after 7 days. Two and seven days after stimulation, high levels of HLA-II were observed in BM-MSCs, intermediate levels were found in fetal-MSCs, and very low levels in iPSC-MSCs. The levels of p-STAT1, interferon regulatory factor 1, and class II transactivator exhibited similar phenomena. Moreover, p-STAT1 antagonist significantly reversed the high expression of HLA-II in BM-MSCs. Compared to adult BM-MSCs, transplanting iPSC-MSCs into hu-PBMNC NSG mice revealed markedly more survival iPSC-MSCs, less inflammatory cell accumulations, and better recovery of hind limb ischemia. The expression of HLA-II in MSCs in the ischemia limbs was detected in BM-MSCs group but not in iPSC-MSCs group at 7 and 21 days after transplantation. Our results demonstrate that, compared to adult MSCs, human iPSC-MSCs are insensitive to proinflammatory IFN-γ-induced HLA-II expression and iPSC-MSCs have a stronger immune privilege after transplantation. It may attribute to a better therapeutic efficacy in allogeneic transplantation.
© 2015 The Authors. STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Entities:  

Keywords:  Human leukocyte antigen class II; Immune humanized mice; Induced pluripotent stem cells; Mesenchymal stem cells

Mesh:

Substances:

Year:  2015        PMID: 26175298     DOI: 10.1002/stem.2094

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  37 in total

1.  Functions of Mesenchymal Stem Cells in Cardiac Repair.

Authors:  Selçuk Öztürk; Ayşe Eser Elçin; Yaşar Murat Elçin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells.

Authors:  Carlos D Luzzani; Santiago G Miriuka
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

Review 3.  Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges.

Authors:  Luiza Bagno; Konstantinos E Hatzistergos; Wayne Balkan; Joshua M Hare
Journal:  Mol Ther       Date:  2018-05-25       Impact factor: 11.454

Review 4.  New Approaches for Enhancement of the Efficacy of Mesenchymal Stem Cell-Derived Exosomes in Cardiovascular Diseases.

Authors:  Lamiaa Ahmed; Khaled Al-Massri
Journal:  Tissue Eng Regen Med       Date:  2022-07-22       Impact factor: 4.451

5.  Interferon-γ enhances the immunosuppressive ability of canine bone marrow-derived mesenchymal stem cells by activating the TLR3-dependent IDO/kynurenine pathway.

Authors:  Jiaqiang Deng; Danting Li; Xiaoya Huang; Weiyao Li; Fangfang Zhao; Congwei Gu; Liuhong Shen; Suizhong Cao; Zhihua Ren; Zhicai Zuo; Junliang Deng; Shumin Yu
Journal:  Mol Biol Rep       Date:  2022-06-12       Impact factor: 2.742

Review 6.  Mesenchymal Stromal Cell Exosomes in Cardiac Repair.

Authors:  Darukeshwara Joladarashi; Raj Kishore
Journal:  Curr Cardiol Rep       Date:  2022-01-29       Impact factor: 3.955

Review 7.  Application Prospects of Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia and the Challenges Encountered.

Authors:  Yajie Tong; Jingye Zuo; Dongmei Yue
Journal:  Biomed Res Int       Date:  2021-05-03       Impact factor: 3.411

8.  iPSC-MSCs with High Intrinsic MIRO1 and Sensitivity to TNF-α Yield Efficacious Mitochondrial Transfer to Rescue Anthracycline-Induced Cardiomyopathy.

Authors:  Yuelin Zhang; Zhendong Yu; Dan Jiang; Xiaoting Liang; Songyan Liao; Zhao Zhang; Wensheng Yue; Xiang Li; Sin-Ming Chiu; Yuet-Hung Chai; Yingmin Liang; Yenyen Chow; Shuo Han; Aimin Xu; Hung-Fat Tse; Qizhou Lian
Journal:  Stem Cell Reports       Date:  2016-09-15       Impact factor: 7.765

Review 9.  Mesenchymal stem cells and immunomodulation: current status and future prospects.

Authors:  F Gao; S M Chiu; D A L Motan; Z Zhang; L Chen; H-L Ji; H-F Tse; Q-L Fu; Q Lian
Journal:  Cell Death Dis       Date:  2016-01-21       Impact factor: 8.469

Review 10.  Mesenchymal stromal cell-derived exosomes in cardiac regeneration and repair.

Authors:  Si-Jia Sun; Rui Wei; Fei Li; Song-Yan Liao; Hung-Fat Tse
Journal:  Stem Cell Reports       Date:  2021-06-10       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.